Eleven Biotherapeutics
Cambridge, US · Delaware corporation · 1 known investors
Find your way into Eleven Biotherapeutics
Sign up to see every warm intro you have to Eleven Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eleven Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DA
David A. BerryFounder
SH
Stephen HurlyExecutive
AP
Arthur P. DeCillisExecutive
GD
Gregory D. PerryExecutive
ES
Eric S. FurfineExecutive
KL
Karen L. TurbridyExecutive
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$34.5M disclosed across 3 rounds · 2014–2018
▶$996KraisedApr 2018 · 10 investors · BiotechnologyRule 506(b)
▶$996KraisedApr 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry J. GertzDirector
- Richard F. FitzgeraldExecutive Officer
- Leslie DanDirector
- Jane V. HendersonDirector
- Wendy L. DixonDirector
- Paul G. ChaneyDirector
- Stephen A. HurlyExecutive Officer, Director
- Abbie C. CelnikerDirector
- Jay S. DukerDirector
- Daniel S. LynchDirector
- Offering amount
- $996K
- Amount sold
- $996K
- Sales commissions
- $36.1K
- Finders' fees
- $30.9K
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.5MraisedSep 2016 · 6 investors · BiotechnologyRule 506(b)
▶$13.5MraisedSep 2016 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel S. LynchDirector
- Paul G. ChaneyDirector
- Stephen HurlyExecutive Officer, Director
- John McCabeExecutive Officer
- Jay S. DukerDirector
- Wendy L. DixonDirector
- Barry J. GertzDirector
- Abbie C. Celniker, Ph.D.Director
- Leslie DanDirector
- Jane V. HendersonDirector
- Arthur P. DeCillisExecutive Officer
- Offering amount
- $13.5M
- Amount sold
- $13.5M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedDec 2014 · 10 investors · BiotechnologyRule 506(b)
▶$20MraisedDec 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David A. BerryExecutive Officer, Director
- Gregory D. PerryExecutive Officer
- Daniel S. LynchDirector
- Eric S. FurfineExecutive Officer
- Abbie C. Celniker, Ph.D.Executive Officer, Director
- Paul ChaneyDirector
- Jane V. HendersonDirector
- Karen L. TurbridyExecutive Officer
- Cary G. PfefferDirector
- Wendy L. DixonDirector
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1.4M
- Placement agents
- Cowen and Company, LLC, Leerink Partners LLC, Citigroup Global Markets Inc.
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Eleven Biotherapeutics went on to found or lead other companies.
Frequently asked questions
- Who founded Eleven Biotherapeutics?
- Eleven Biotherapeutics was founded by David A. Berry.
- Who are Eleven Biotherapeutics's investors?
- Eleven Biotherapeutics's investors include Third Rock Ventures.
- How much funding has Eleven Biotherapeutics raised?
- Eleven Biotherapeutics has disclosed $34.5M raised across 3 rounds.
- Where is Eleven Biotherapeutics headquartered?
- Eleven Biotherapeutics is headquartered in Cambridge, US.




